TECHWIRE 30
(CIX: WRAL30)  1,117.26  down arrow-0.53  (-0.05 %)  Updated: 08:10 PM EDT, Sep 23 2014
(NQ: Apple)  102.64  up arrow+1.58  (1.56 %)  Updated: 08:10 PM EDT, Sep 23 2014
(NY: QUINTILES)  55.76  down arrow-0.53  (-0.94 %)  Updated: 06:40 PM EDT, Sep 23 2014
(OP: BASF SE)  97.20  down arrow-1.14  (-1.16 %)  Updated: 08:10 PM EDT, Sep 23 2014
(NQ: BioCryst)  10.22  down arrow-0.22  (-2.11 %)  Updated: 08:10 PM EDT, Sep 23 2014
(NQ: BioDelivery)  16.51  down arrow-0.15  (-0.9 %)  Updated: 08:10 PM EDT, Sep 23 2014
(NQ: CEMP)  9.71  down arrow-0.27  (-2.71 %)  Updated: 08:10 PM EDT, Sep 23 2014
(NQ: Cisco Systems)  24.70  down arrow-0.27  (-1.08 %)  Updated: 08:10 PM EDT, Sep 23 2014
(NQ: Cree)  42.00  up arrow+0.65  (1.57 %)  Updated: 08:10 PM EDT, Sep 23 2014
(NQ: DARA)  1.06  down arrow-0.03  (-2.89 %)  Updated: 08:10 PM EDT, Sep 23 2014
(NY: EMC CORPORATION)  29.85  up arrow+0.17  (0.57 %)  Updated: 06:40 PM EDT, Sep 23 2014
(NQ: Extreme Networks)  4.54  down arrow-0.11  (-2.37 %)  Updated: 08:10 PM EDT, Sep 23 2014
(NQ: FB)  78.29  up arrow+1.49  (1.94 %)  Updated: 08:10 PM EDT, Sep 23 2014
(NY: GLAXOSMITHKLINE)  46.64  down arrow-0.68  (-1.44 %)  Updated: 06:40 PM EDT, Sep 23 2014
(NQ: GOOG)  581.13  down arrow-6.24  (-1.06 %)  Updated: 08:10 PM EDT, Sep 23 2014
(NY: IBM)  191.62  down arrow-1.49  (-0.77 %)  Updated: 06:40 PM EDT, Sep 23 2014
(NY: LH)  102.96  down arrow-1.54  (-1.47 %)  Updated: 06:40 PM EDT, Sep 23 2014
(OP: Lenovo Group)  30.77  up arrow+0.16  (0.51 %)  Updated: 08:10 PM EDT, Sep 23 2014
(NY: MRK)  60.28  down arrow-0.3  (-0.5 %)  Updated: 06:40 PM EDT, Sep 23 2014
(NQ: Microsoft Corp)  46.56  down arrow-0.5  (-1.06 %)  Updated: 08:10 PM EDT, Sep 23 2014
(NQ: NTAP)  43.07  up arrow+0.07  (0.16 %)  Updated: 08:10 PM EDT, Sep 23 2014
(NY: NOVARTIS AG)  93.41  down arrow-0.65  (-0.69 %)  Updated: 06:40 PM EDT, Sep 23 2014
(OP: Novozymes A/S)  44.22  down arrow-0.48  (-1.07 %)  Updated: 08:10 PM EDT, Sep 23 2014
(NY: PFIZER)  30.05  down arrow-0.13  (-0.43 %)  Updated: 06:40 PM EDT, Sep 23 2014
(NQ: Pozen)  7.94  down arrow-0.06  (-0.75 %)  Updated: 08:10 PM EDT, Sep 23 2014
(NY: RED HAT)  56.33  down arrow-0.34  (-0.6 %)  Updated: 06:40 PM EDT, Sep 23 2014
(NQ: BBRY)  10.56  down arrow-0.37  (-3.39 %)  Updated: 08:10 PM EDT, Sep 23 2014
(NQ: Salix)  169.17  up arrow+9.34  (5.84 %)  Updated: 08:10 PM EDT, Sep 23 2014
(NQ: SQI)  15.22  down arrow-0.42  (-2.69 %)  Updated: 08:10 PM EDT, Sep 23 2014

Posts tagged “Talecris”

March 7, 2013

Premium Lock Facebook goes for 'personalized newspaper' design

Facebook is revamping its News Feed to include bigger photos, sorting by topics and a more consistent design across devices as the world's most popular social network ramps up efforts to make money from content.

Facebook's new look Facebook's new look

February 28, 2012

Premium Lock How long before Salix Pharmaceuticals hits $1B?

Salix After a 60 percent jump in revenue in 2011 to $540 million, the Raleigh-based drug firm forecasts a 36 percent jump in 2012 to $735 million.

May 2, 2011

Premium Lock FTC tentatively approves Talecris-Grifols merger

Talecris Talecris Biotherapeutics' $4 billion merger with Grifols SA of Spain has won tentative approval from U.S. antitrust regulators.

Tags: Talecris
February 15, 2011

Premium Lock FTC may challenge Grifols buy of Talecris

FTC Sources close to the deal say U.S. antitrust regulators may challenge Spanish healthcare firm Grifols' planned buy of Talecris Biotheraputics.

February 14, 2011

Premium Lock Talecris stockholders agree to Grifols merger

Talecris Talecris shareholders vote in RTP on Monday to proceed with proposed merger with Grifols, but still await final approval by U.S. Federal Trade Commission.

Updated June 7, 2010

Premium Lock Talecris Biotherapeutics sells to Spanish firm for $4 billion

Talecrids shares surge 26 percent after the news. The RTP-based manufacturer of plasma-based drug therapies agrees to be acquired by Spainish healthcare giant Grifols SA.

Talecris Talecris

Updated June 7, 2010

Premium Lock Talecris execs 'fully expect' Clayton expansion to proceed

Grifols The blood plasma thereapeutics firm says its $4 billion acquisition by a Spanish firm is about “growth and creating a global platform.” However, government approval may not come quickly.

Updated September 30, 2009

Premium Lock Talecris readies for long-delayed IPO

Talecris Talecris Biotherapeutics Inc. is expected to go public this week, offering 28.9 million shares for $18 to $20 apiece.

Updated September 15, 2009

Premium Lock Talecris launches initial public offering 'road show', aiming for nearly $900 million

 RTP-based maker of plasma-based therapeutics withdrew a $1 billion IPO in 2007. A $3.1 billion merger with Australian rival fell through earlier this summer. Talecris plans to trade on Nasdaq under symbol TLCR.

Updated September 11, 2009

Premium Lock Talecris looks to raise some $900 million in stock offering

 RTP-based firm, which is world’s third largest manufacturer of plasma-based therapies, seeks to go public. In June, its $3.1 billion merger with Australian rival CSL fell through when challenged by U.S. FTC.

Techwire Inside Partners
The Skinny: A Blog by Rick Smith

OUR INSIDERS

Dr. Mike Walden
Tech economy
Vivek Wadhwa
Commentary
Frank Vinluan
Life science
Scroll